[go: up one dir, main page]

PL346011A1 - Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions - Google Patents

Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Info

Publication number
PL346011A1
PL346011A1 PL99346011A PL34601199A PL346011A1 PL 346011 A1 PL346011 A1 PL 346011A1 PL 99346011 A PL99346011 A PL 99346011A PL 34601199 A PL34601199 A PL 34601199A PL 346011 A1 PL346011 A1 PL 346011A1
Authority
PL
Poland
Prior art keywords
coadministration
acat
treatment
atherosclerotic lesions
mmp inhibitors
Prior art date
Application number
PL99346011A
Other languages
English (en)
Inventor
Thomas Michael Andrew Bocan
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PL346011A1 publication Critical patent/PL346011A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL99346011A 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions PL346011A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (1)

Publication Number Publication Date
PL346011A1 true PL346011A1 (en) 2002-01-14

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99346011A PL346011A1 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Country Status (25)

Country Link
EP (1) EP1098662A2 (xx)
JP (1) JP2002521328A (xx)
KR (1) KR20010083134A (xx)
CN (1) CN1310629A (xx)
AP (1) AP2001002035A0 (xx)
AU (1) AU4701799A (xx)
BG (1) BG105162A (xx)
BR (1) BR9912296A (xx)
CA (1) CA2335062A1 (xx)
CZ (1) CZ2001126A3 (xx)
EA (1) EA200100153A1 (xx)
EE (1) EE200100046A (xx)
HR (1) HRP20010055A2 (xx)
HU (1) HUP0102880A3 (xx)
ID (1) ID30030A (xx)
IL (1) IL140982A0 (xx)
IS (1) IS5809A (xx)
NO (1) NO20010291D0 (xx)
OA (1) OA11584A (xx)
PL (1) PL346011A1 (xx)
SK (1) SK502001A3 (xx)
TR (1) TR200100205T2 (xx)
WO (1) WO2000004892A2 (xx)
YU (1) YU3501A (xx)
ZA (1) ZA200100294B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2382676A1 (en) * 1999-11-05 2001-05-17 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
CO5261615A1 (es) 1999-12-01 2003-03-31 Agouron Pharma Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas
WO2001044178A1 (en) * 1999-12-17 2001-06-21 Versicor, Inc. Novel urea compounds, compositions and methods of use and preparation
PL362244A1 (en) * 2000-09-01 2004-10-18 Sankyo Company, Limited Medicinal compositions
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
MXPA04009490A (es) * 2002-04-03 2005-06-08 Topo Target Uk Ltd Compuesto de acido carbamico que comprenden un enlace de piperazina como inhibidores de histona desacetilasa.
JP4617449B2 (ja) * 2002-07-11 2011-01-26 ヴィキュロン ファーマシューティカルズ インコーポレイテッド 抗菌活性を有するｎ−ヒドロキシアミド誘導体
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
US20180000817A1 (en) * 2015-01-15 2018-01-04 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
EA002435B1 (ru) * 1995-08-04 2002-04-25 Варнер-Ламберт Компани Способ снижения уровня липопротеина (а) в сыворотке или в плазме крови млекопитающих
CZ294063B6 (cs) * 1996-05-17 2004-09-15 Warner-Lambert Company Bifenylsulfonamid, jeho použití a farmaceutický prostředek s jeho obsahem
EP0931045A1 (en) * 1996-09-04 1999-07-28 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses

Also Published As

Publication number Publication date
IS5809A (is) 2001-01-12
AU4701799A (en) 2000-02-14
YU3501A (sh) 2005-06-10
IL140982A0 (en) 2002-02-10
EP1098662A2 (en) 2001-05-16
CZ2001126A3 (cs) 2002-01-16
NO20010291L (no) 2001-01-18
BG105162A (en) 2001-12-29
JP2002521328A (ja) 2002-07-16
OA11584A (en) 2004-07-20
WO2000004892A2 (en) 2000-02-03
SK502001A3 (en) 2002-06-04
BR9912296A (pt) 2001-04-17
KR20010083134A (ko) 2001-08-31
WO2000004892A3 (en) 2000-05-18
NO20010291D0 (no) 2001-01-18
HUP0102880A2 (en) 2002-06-29
ZA200100294B (en) 2002-01-10
EE200100046A (et) 2002-06-17
AP2001002035A0 (en) 2001-03-31
CA2335062A1 (en) 2000-02-03
ID30030A (id) 2001-11-01
HRP20010055A2 (en) 2002-04-30
TR200100205T2 (tr) 2001-05-21
HUP0102880A3 (en) 2002-11-28
CN1310629A (zh) 2001-08-29
EA200100153A1 (ru) 2001-08-27

Similar Documents

Publication Publication Date Title
GB9800795D0 (en) Prevention of multiple use of limited use devices
AU3034300A (en) Substituted benzimidazoles and their use as parp inhibitors
HUP0101613A3 (en) Metalloprotease inhibitor (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides and medicaments containing the same
AU2212299A (en) Compositions and methods for the treatment of tumor
HU0900792D0 (en) Use of renin-angiotensin inhibitors
HU9802971D0 (en) The use of mmp inhibitors for the treatments of ocular angiogenesis
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
AU3124300A (en) Inhibitors of beta-lactamases and uses therefor
GB2342045B (en) Mineral and vitamin combinations for the treatment of stress and allergies
HUP0102880A2 (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
AU2190400A (en) Inhibitors of beta-lactamases and uses therefor
HUP0103473A3 (en) Phosphoglycolipid and methods for its use
GB9816234D0 (en) Compounds for use in the treatment of inflammation
IT1302811B1 (it) Procedimento e relativo apparato per la riduzione direttadi ossidi di ferro
IL141426A0 (en) Compositions and methods for the treatment of tumor
IL143212A0 (en) Compositions and methods for the treatment of tumor
HUP0101947A3 (en) Combination for the treatment of tumors
NO20004920D0 (no) Anvendelse av proteaseinhibitorer for behandling av hudskader
GB9823036D0 (en) Fluticasone lotion having improved vasoconstrictor activity
AU7688998A (en) Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
IL141056A0 (en) Protease inhibitors for use in the treatment of psoriasis
IT1302813B1 (it) Dispositivo per la riduzione diretta di ossidi di ferroe relativo procedimento
AU1940800A (en) Combination therapy for the treatment of sepsis
GB2343629B (en) Treatment of cellulite
EP1135141A4 (en) PHOSPHOLIPASE INHIBITORS FOR TREATING CANCER